Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka) is an oral targeted therapy that inhibits several tyrosine kinases including BCR-ABL, c-KIT, and the Src family kinases. The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation, the inhibition of apoptosis, and adhesion and cytoskeleton abnormalities, all of which are characteristics of the disease. The presence of this gene is a result of the Philadelphia chromosome translocation, which is found in over 90% of chronic myeloid leukemia (CML) cases.
LIST OF FIGURES
10 Figure 1: Sprycel for CML – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Sprycel for CML
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Sprycel for CML
19 Figure 4: Sprycel – SWOT analysis in acute lymphoblastic leukemia
20 Figure 5: Datamonitor Healthcare’s drug assessment summary for Sprycel in acute lymphoblastic leukemia
21 Figure 6: Datamonitor Healthcare’s drug assessment summary for Sprycel in acute lymphoblastic leukemia
LIST OF TABLES
5 Table 1: Sprycel drug profile
7 Table 2: Sprycel pivotal trial data in CML
9 Table 3: Sprycel ongoing late-phase trial in CML
13 Table 4: Sprycel and Tasigna trial data in first-line CML
17 Table 5: Sprycel drug profile
18 Table 6: Overview of pivotal trial data for Sprycel in acute lymphoblastic leukemia
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.